VF
KALV

Virtu Financial’s KalVista Pharmaceuticals KALV Stock Holding History

Virtu Financial’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,739
Closed -$347K – 1790
2025
Q2 		$347K Buy
+30,739
New +$376K 0.02% 699
2021
Q2 		– Sell
-13,262
Closed -$341K – 1791
2021
Q1 		$341K Buy
+13,262
New +$348K 0.02% 738
2018
Q4 		– Sell
-9,755
Closed -$216K – 1779
2018
Q3 		$216K Buy
+9,755
New +$132K 0.01% 1045

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial's KALV Position: Q3 2025 in Review

Virtu Financial sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 30,739 shares — an estimated $347K sold.

Virtu Financial first reported a position in KALV in Q3 2018 and held it in 3 quarters. The position peaked at $347K in Q2 2025. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • Virtu Financial reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Virtu Financial sold 30,739 KalVista Pharmaceuticals shares in Q3 2025, an estimated $347K.
  • Virtu Financial first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Virtu Financial's KalVista Pharmaceuticals position peaked at $347K in Q2 2025.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.